Evaluating comorbidities in total hip and knee arthroplasty: available instruments by Bjorgul, Kristian et al.
REVIEW ARTICLE
Evaluating comorbidities in total hip and knee arthroplasty:
available instruments
Kristian Bjorgul • Wendy M. Novicoff •
Khaled J. Saleh
Received: 18 March 2010/Accepted: 19 October 2010/Published online: 13 November 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Each year millions of patients are treated for
joint pain with total joint arthroplasty, and the numbers are
expected to rise. Comorbid disease is known to inﬂuence
the outcome of total joint arthroplasty, and its documen-
tation is therefore of utmost importance in clinical evalu-
ation of the individual patient as well as in research. In this
paper, we examine the various methods for obtaining and
assessing comorbidity information for patients undergoing
joint replacement. Multiple instruments are reliable and
validated for this purpose, such as the Charlson Index,
Index of Coexistent Disease, and the Functional Comor-
bidity Index. In orthopedic studies, the Charnley classiﬁ-
cation and the American Society of Anesthesiologists
physical function score (ASA) are widely used. We rec-
ommend that a well-documented comorbidity index that
incorporates some aspect of mental health is used along
with other appropriate instruments to objectively assess the
preoperative status of the patient.
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Introduction
Each year, joint pain from multiple causes decreases the
quality of life of millions of patients [1]. Total joint
arthroplasty remains one of the most commonly per-
formed and universally successful operative interventions
for patients with osteoarthritis and other joint problems,
with over 600,000 total knee procedures and nearly
300,000 total hip procedures performed in 2007 [2]. The
rapid increase in joint surgeries each year can be
attributed to the rising population age of the country and
the increasing prevalence of arthritis and other factors
that lead to the need for these procedures [3]. In addi-
tion, the perceived and real success of total joint
arthroplasty—improved functional status, pain relief, low
perioperative morbidity and mortality, and good implant
survivorship—has expanded demand among all popula-
tion segments [4].
Comorbidities are deﬁned as diseases or medical con-
ditions unrelated in etiology or causality to the principal
diagnosis that coexist with the disease of interest. It is
important to identify the comorbidities of the patient,
because they may delay diagnosis, alter treatment, lead to
complications, inﬂuence survival, and confound analysis of
outcomes [5]. There is ample evidence that comorbidity is
a major factor in determining the outcomes of various
conditions, and there is a large body of literature discussing
the multiple aspects of comorbidity. The general ﬁnding is
a close relationship between comorbidities and complica-
tions [6], mortality [7], functional outcome [8], and con-
sumption of healthcare resources [9, 10].
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DOI 10.1007/s10195-010-0115-xTotal joint replacement generally improves health-rela-
ted quality of life, but when improvement is modest, the
role of comorbidities is often highlighted [11, 12]. Since
the prevalence of comorbidities increases with advancing
age, with estimates ranging from 60% to 88% of the pop-
ulation aged 65 years and above having at least one
comorbidity [9], it is expected that a signiﬁcant proportion
of arthroplasty patients have comorbidities [13]. It is clear,
however, that the rate of comorbidities is different for hip
replacement patients compared with knee replacement
patients, with hip replacement patients generally having
lower rates of comorbidities.
Although it is generally known that mortality is quite
low following total joint replacement, studies have found
that the presence of comorbidities can increase the chance
of mortality [14, 15]. Kreder et al. found that mortality
increased 24 times in the presence of comorbidities com-
pared with patients with no comorbidities.
Collecting data on comorbidities
Data pertaining to comorbidities might be collected by
directly interviewing the patient, by patient self-reporting,
reviewing medical charts or by extraction from databases
[7, 16]. It is generally believed that administrative data,
such as data submitted for insurance claims and billing
purposes, generally agree with patient chart data for
recording of comorbidities, but there is evidence that
comorbidities are underreported in administrative data,
especially in terms of speciﬁcity of prior events such as
myocardial infarction [17, 18]. Since most administrative
data rely on discharge diagnoses, accurate documentation
and subsequent coding of diagnoses are critical. There
might be inaccuracies in coding depending on whether the
coding is done by a dedicated coding team and whether or
not orthopedic surgeons are part of this team [19, 20]. One
potential pitfall when studying discharge diagnoses as the
primary means for identifying patient medical history is the
fact that complications and their sequelae may be mistaken
for comorbidities [21]. A complication refers to a condition
that arises secondarily to the main diagnoses and may be
related to the diagnosis or the treatment, whereas comor-
bidity is a preexisting condition that may modulate the
outcome of treatment. This becomes an important distinc-
tion in risk adjustment and other statistical models that
attempt to stratify patients based on risk of mortality or
severity of illness [21].
Patient self-reporting is an attractive alternative to
chart review and discharge diagnosis, since the patient is
the primary source of information. Research has shown
that patients can accurately and reliably report their
medical conditions [22–24]. Several speciﬁc instruments
have been developed to assist the patient in objectively
recording their medical history. Greenﬁeld and his col-
leagues developed the Self-Administered Comorbidity
Questionnaire, which uses patients’ reports of symptoms
and conditions, as well as patients’ ratings of symptom
intensity to characterize total disease burden without
depending on a current diagnosis [23]. This questionnaire
uses closed-end questions speciﬁc to organ system or
disease group and has been shown to have modest cor-
relation with widely used medical-record-based comor-
bidity instruments [25].
Available comorbidity instruments
In an increasingly competitive environment, clinical out-
comes assessment of healthcare providers is an important
issue. When adjusting for differences in demographic and
clinical risk factors among patients treated across provid-
ers, it is vital to use a validated and reliable tool. To that
end, clinical quality indicators including comorbidities
have been developed [21, 26].
A comorbidity index is an instrument that condenses the
patient’s comorbidities into a single, numeric score. It is
derived from the number of coexistent diseases as well as
their individual severity and allows comparisons with
scores from other patients. A comorbidity index is a
research tool used to stratify patients of similar risk, or
allow for adjustment of varying risk, and they are thought
to be too imprecise to replace clinical judgment for a
speciﬁc patient [27]. Even so, some studies acknowledge
the need for accounting for comorbidities, but elect not to
use a formal instrument, merely counting each patient’s
additional diagnoses [28, 29].
In a review on methods to measure comorbidity, de
Groot et al. [30] found four instruments to be sufﬁciently
valid and reliable, of which only the Charlson Index and
the Index of Coexistent Disease (ICED) have reached some
recognition in the orthopedic literature [31, 32].
The Charlson Index
The Charlson Index was developed to quantify the inﬂu-
ence of comorbidities on survival [31]. There are 19
deﬁned comorbid conditions, which were selected based on
their observed association with a 1-year mortality risk in a
cohort of hospitalized patients in one New England hos-
pital in 1984. Each comorbid disease is assigned a weight
from 1 to 6, and the index is the sum of the weights for
each comorbid condition and can range from 0 to 33. It has
been widely used in large studies based on administrative
data to predict functional outcome [33], implant survival
[34], mortality [35], and length of hospital stay and
resource use [7, 16]. The reliability has been shown to be
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123excellent [36], and several studies conﬁrm that it is valid
[30]. The Charlson Index might be a poor predictor of
quality-of-life outcomes in patients undergoing primary hip
and knee replacement, and it has been found to be less
responsive than other measures of comorbidities, possibly
because it is more sensitive to life-threatening conditions
than to functional outcomes [37, 38]. A questionnaire
version of the Charlson Index was found to be reproducible
and valid, and it offers practical advantages over medical-
record-based questionnaires [24].
Index of Coexistent Disease (ICED)
The Index of Coexistent Disease (ICED) is an index that
speciﬁcally controls for comorbidity when the outcome is
functional status [9, 30, 39]. It was developed based on the
variations in length of stay and outcome of six medical and
surgical conditions, one of which was total hip replacement
[40]. The ICED consists of two different dimensions. One
measures the disease severity of 14 categories of comorbid
diseases, and the other measures the overall functional
severity (disability). Scores are based on a list of symp-
toms, signs, and laboratory tests and are summarized into a
four-point scale, from 0 to 3. Though its validity and
reliability were deemed good [30], we have not found the
ICED to be very prevalent in the orthopedic literature. We
have identiﬁed 17 articles in which ICED is a comorbidity
instrument. Two articles deal with arthritis and one with
total hip replacement.
The Functional Comorbidity Index
The Functional Comorbidity Index (FCI) was developed
with physical function as the only outcome of interest
[41]. Functional outcome generally is more interesting
than mortality in orthopedic research, and a comorbidity
index that could explain variation in physical outcome
would be valuable to orthopedic surgeons. The FCI con-
sists of a list of 18 diagnoses that were found to be sig-
niﬁcantly associated with declining function. One point is
assigned to each diagnosis, and the points are summa-
rized, giving the patient a score between 0 and 18. In
developing the scale, the authors attempted to apply
weight to the diseases after having identiﬁed their relative
association with physical function. Interestingly, the
weighted scores did not perform better than the non-
weighted scores, indicating that a simple count of diag-
noses is sufﬁcient. The FCI has been shown to perform
better than the Charlson Index when physical function
was the outcome [42], but to our knowledge it has not
been used in orthopedic research. The FCI includes
mental health as well as obesity among the comorbidities
that make up the index.
The Charnley classiﬁcation
The Charnley classiﬁcation is commonly used in the
orthopedic literature, even though it cannot be regarded as
a comorbidity index proper. It stratiﬁes patients into three
categories in order to gain better understanding of the
variability in outcome, which was quantiﬁed as walking
ability [43, 44]. Patients are assigned to class A if they
have single joint arthropathy and no signiﬁcant medical
comorbidity. Class B patients have one other joint in need
of an arthroplasty, or an unsuccessful or failing arthroplasty
in another joint, while class C patients have multiple joints
in need of arthroplasty, multiple failing arthoplasties or
signiﬁcant medical or psychological impairment. It has
been suggested that category B should be dichotomized
into B1 and B2 according to whether the contralateral hip
has been successfully treated with an arthroplasty (B2) or
remains untreated (B1) [8, 45].
The Charnley class of the patient inﬂuences the outcome
as measured by Short Form-36 (SF-36) [46], Harris Hip
Score [47, 48] as well as the Nottingham Health Proﬁle
Score [49] and the Western Ontario and McMaster Uni-
versities Osteoarthritis Index (WOMAC) [48]. Charnley
class also signiﬁcantly affects the function, pain, and range
of motion subscales of the Harris Hip Score [47]. Fur-
thermore, progressive deterioration in walking capacity
with time has been noted, and this deterioration was also
most pronounced for Charnley category C patients [47].
The distribution of patients in the Charnley classiﬁcation
varies over time as patients develop new comorbidities or
preexistent comorbidities worsen [47]. When the Charnley
scale was used as a patient-administered questionnaire for a
6-year follow-up, 52% of respondents placed themselves in
Charnley category C [50].
The crucial point in the Charnley classiﬁcation is how to
determine whether a comorbid illness is signiﬁcant or not.
An illness that signiﬁcantly impairs the patient’s ability to
walk should cause the patient to be placed in category C.
This leaves it to the physician to decide whether various
diseases are signiﬁcant or not. A disease such as diabetes
mellitus, which is known to inﬂuence outcome in several
ways, might not lead to the patient being placed in
Charnley class C if the patient is ﬁt and manages the dis-
ease well. Thus, there is a question of whether this clas-
siﬁcation system is liable to suffer from interobserver
variability to a larger extent than other systems. We are not
aware of any study that has investigated the interobserver
reliability of the Charnley classiﬁcation.
The Charnley classiﬁcation may also be used to assess
levels of activity [51], which is in accordance with the
authors’ original intention [43]. Loosening of arthroplasty
components has been shown to be more frequent in
Charnley group A than group B, and group C patients,
J Orthopaed Traumatol (2010) 11:203–209 205
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levels of activity [52].
Since the Charnley classiﬁcation relies on an assessment
of the severity of the associated conditions, it might not be
suitable in studies based on chart reviews or extraction of
medical records.
Dunbar et al. modiﬁed the Charnley classiﬁcation
instrument for use as a questionnaire to assess comorbidi-
ties in knee replacement surgery [8]. Originally designed as
a physician-based instrument to assess degree of impair-
ment in locomotion, it might be regarded as an organ-
speciﬁc comorbidity instrument. The authors did not
compare the modiﬁed instrument with other comorbidity
indices, but found that clinical outcomes varied signiﬁ-
cantly with comorbidity levels.
The Charnley classiﬁcation has been modiﬁed for use
with knee arthroplasty patients [8]. This study showed that
Charnley class signiﬁcantly affected outcomes in SF-36,
WOMAC, Oxford Knee Score, and a Global Knee Score
[8]. This ﬁnding is in accordance with other studies that
showed that two or more comorbidities signiﬁcantly cor-
related with decreasing knee scores [29]. In the Knee
Society rating scale, patients are similarly categorized into
three groups based on the same criteria. However, this
scale admits patients with successfully operated contralat-
eral knees into class A [53].
The American Society of Anesthesiologists physical
status classiﬁcation
The American Society of Anesthesiologists physical status
classiﬁcation (ASA) was designed to assess the physical
status of the patient. First published in 1941, it has
remained virtually unaltered since a minor change was
accepted in 1961 [54]. It is now widely used globally as a
standard preoperative measurement [55]. Hence, it is
readily available from medical charts. It ranks patients in
ﬁve groups based on severity of diseases (Table 1).
ASA physical status has been shown to be useful in
assessing risk of intra- and postoperative nonorthopedic
complications [6, 56] as well as morbidity [57], mortality,
cost, and length of stay [55]. The ability of ASA to predict
infection in total joint surgery is controversial, as some
studies ﬁnd an association [58, 59] whereas others do not
[60, 61]. Although the ASA might suffer from lack of
precision and low reliability [62, 63], it has been shown to
predict dislocations in total joint arthroplasty [64] as well
as the need for a rehabilitation service postoperatively.
The similarities and differences between the Charlson
comorbidity index and the ASA classiﬁcation are eluci-
dated in a study by Weaver et al. [65]. In this study, 78% of
patients had Charlson score of 0, and 22% had a score of 2
or worse. The proportion of patients was 3%, 45%, 49%,
and 3% in ASA classes 1–4. The discrepancy between the
comorbidity index and the anesthesiologic risk assessment
instrument is striking. Nevertheless, the main ﬁnding in the
study was that preoperative comorbid conditions relate to
poor outcomes after total joint arthroplasty.
Interestingly, three large arthroplasty registries in
Scandinavia have chosen different ways of assessing pre-
operative health status. The Norwegian Joint Replacement
Registry utilizes the ASA score [66], whereas the Swedish
Hip Registry uses the Charnley classiﬁcation [50] and the
Danish Hip Arthroplasty Register makes use of the
Charlson Index [34].
As the role of mental health in outcomes studies after
joint replacement becomes increasingly elucidated, it
seems pertinent that mental health should be regarded as a
comorbidity and accounted for in a comorbidity index.
Studies have shown that impaired mental health negatively
affects outcome after knee as well as hip replacement [67].
Selection of instruments
There is little doubt that comorbidities are important in
modulating outcome in total joint surgery. However,
comorbidities constitute a wide range of conditions that
might inﬂuence outcome in a variety of ways. Hyperten-
sion and diabetes mellitus are among the most frequent
comorbidities. It is very hard to ﬁnd any study on the
impact of hypertension on outcomes in total joint surgery,
whereas diabetes mellitus is a well-studied entity. It is a
comorbid disease that is signiﬁcantly related to complica-
tions in several diseases [9], and preoperative factors such
as obesity and associated diseases may adversely affect the
clinical outcome of total knee arthroplasty (TKA) as well
as hip replacement in diabetic patients [68, 69].
There are multiple ways of assessing the preoperative
health status of the patient. Some instruments, such as the
SF-36, are generic and express the general health of the
patient with any diagnosis. The SF-36 covers both physical
and mental components of health and may be used for
identifying speciﬁc problems that need closer follow-up,
such as anxiety or depression that might beneﬁt from closer
Table 1 ASA score
1 A normally healthy patient
2 A patient with mild systemic disease
3 A patient with severe systemic disease that limits activity but is not
incapacitating
4 A patient with an incapacitating systemic disease that is a constant
threat to life
5 A moribund patient who is not expected to survive 24 h with or
without treatment
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eratively. Health-related quality-of-life instruments might
also be used to this end [70].
Other instruments like the WOMAC and the Hip Os-
teeoarthritis Outcomes Scale (HOOS) are disease-, or even
joint speciﬁc. Hip and knee rating scales may be used
preoperatively to obtain a baseline value, and these scales
are expected to correlate well with less speciﬁc scales.
Furthermore, some of the speciﬁc scales attempt to incor-
porate more general aspects of patient health. The Knee
Society rating scale contains a scale for stratiﬁcation of
patients according to comorbidities that closely resembles
the Charnley classiﬁcation, whereas the Hip Injury and
Osteoarthritis Outcomes Scale (HOOS) and Hip Injury and
Osteoarthritis Outcomes Scale (KOOS) [71] incorporate
elements from the WOMAC.
Both general scales and more speciﬁc rating scales may
be used postoperatively in order to monitor the effect of
treatment. In contrast, the comorbidity instruments are
generally not expected to change following surgery. These
indices express the basic health status of the patient and are
modulators of the pre- and postoperative course. The ASA
score is a measure of patient health with a focus on severity
of disease as it relates to operative risk and is not likely to
change, whereas it is known that the Charnley class of the
patient may change with long-term follow-up. Activity
scales express actual levels of patient activity, which may
change in the event of successful surgery. Hence, they may
be used as outcome measures as well.
None of these instruments is all-inclusive, and they all
seem to relate various aspects of patient health status. In
order to provide a complete picture it is necessary to use a
combination of instruments. For routine clinical use, we
recommend using the ASA as a comorbidity instrument,
supplemented by an instrument that covers possible mental
health issues, such as the SF-12 or the SF-36. For research
purposes, we think that scientists should consider using one
of the validated instruments developed speciﬁcally for
orthopedic use such as the Index of Coexistent Disease
(ICED) or the Functional Comorbidity Index (FCI).
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